On Tuesday 13 December, the European Commission proposed a revision of the system of fees and charges payable to the European Medicines Agency (EMA), to bring it into line with recent changes to the regulatory framework.
These fees are paid to the EMA by the holders of a market authorisation for a pharmaceutical product. The sums collected enable the EMA to remunerate the national competent authorities for their contribution to the scientific evaluation of pharmaceutical products with a...